HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

Medulloblastomas are the most common malignant brain tumors in childhood. Emerging evidence suggests that medulloblastoma comprises at least four distinct diseases (WNT, SHH, Group 3 and 4) with different biology, clinical presentation, and outcome, with especially poor prognosis in Group 3. The tig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Milde, Till (VerfasserIn) , Lodrini, Marco (VerfasserIn) , Korshunov, Andrey (VerfasserIn) , Kool, Marcel (VerfasserIn) , Pfister, Stefan (VerfasserIn) , Kulozik, Andreas (VerfasserIn) , Witt, Olaf (VerfasserIn) , Deubzer, Hedwig (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2012
In: Journal of neuro-oncology
Year: 2012, Jahrgang: 110, Heft: 3, Pages: 335-348
ISSN:1573-7373
DOI:10.1007/s11060-012-0978-1
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s11060-012-0978-1
Verlag, Volltext: https://doi.org/10.1007/s11060-012-0978-1
Volltext
Verfasserangaben:Till Milde, Marco Lodrini, Larissa Savelyeva, Andrey Korshunov, Marcel Kool, Lena M. Brueckner, André S. L. M. Antunes, Ina Oehme, Arnulf Pekrun, Stefan M. Pfister, Andreas E. Kulozik, Olaf Witt, Hedwig E. Deubzer

MARC

LEADER 00000caa a2200000 c 4500
001 1584629665
003 DE-627
005 20250206100708.0
007 cr uuu---uuuuu
008 181129s2012 xx |||||o 00| ||eng c
024 7 |a 10.1007/s11060-012-0978-1  |2 doi 
035 |a (DE-627)1584629665 
035 |a (DE-576)514629665 
035 |a (DE-599)BSZ514629665 
035 |a (OCoLC)1341024718 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Milde, Till  |d 1973-  |e VerfasserIn  |0 (DE-588)1038311837  |0 (DE-627)75711234X  |0 (DE-576)39229334X  |4 aut 
245 1 0 |a HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment  |c Till Milde, Marco Lodrini, Larissa Savelyeva, Andrey Korshunov, Marcel Kool, Lena M. Brueckner, André S. L. M. Antunes, Ina Oehme, Arnulf Pekrun, Stefan M. Pfister, Andreas E. Kulozik, Olaf Witt, Hedwig E. Deubzer 
264 1 |c December 2012 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.11.2018 
520 |a Medulloblastomas are the most common malignant brain tumors in childhood. Emerging evidence suggests that medulloblastoma comprises at least four distinct diseases (WNT, SHH, Group 3 and 4) with different biology, clinical presentation, and outcome, with especially poor prognosis in Group 3. The tight connection of biology and clinical behavior in patients emphasizes the need for subgroup-specific preclinical models in order to develop treatments tailored to each subgroup. Herein we report on the novel cell line HD-MB03, isolated from tumor material of a patient with metastasized Group 3 medulloblastoma, and preclinical testing of different histone deacetylase inhibitors (HDACis) in this model. HD-MB03 cells grow long term in vitro and form metastatic tumors in vivo upon orthotopic transplantation. HD-MB03 cells reflect the original Group 3 medulloblastoma at the histological and molecular level, showing large cell morphology, similar expression patterns for markers Ki67, p53, and glial fibrillary acidic protein (GFAP), a gene expression profile most closely matching Group 3 medulloblastomas, and persistence of typical molecular alterations, i.e., isochromosome 17q [i(17q)] and MYC amplification. Protein expression analysis of HDACs 2, 5, 8, and 9 as well as the predictive marker HR23B showed intermediate to strong expression, suggesting sensitivity to HDACis. Indeed, treatment with HDACis Helminthosporium carbonum (HC)-toxin, vorinostat, and panobinostat revealed high sensitivity to this novel drug class, as well as a radiation-sensitizing effect with significantly increased cell death upon concomitant treatment. In summary, our data indicate that HD-MB03 is a suitable preclinical model for Group 3 medulloblastoma, and HDACis could represent a therapeutic option for this subgroup. 
650 4 |a Group 3 
650 4 |a HC-toxin 
650 4 |a Irradiation 
650 4 |a Medulloblastoma 
650 4 |a MYC 
650 4 |a Panobinostat 
650 4 |a Vorinostat 
700 1 |a Lodrini, Marco  |d 1974-  |e VerfasserIn  |0 (DE-588)134038398  |0 (DE-627)559880383  |0 (DE-576)300271018  |4 aut 
700 1 |a Korshunov, Andrey  |e VerfasserIn  |0 (DE-588)1043235361  |0 (DE-627)770439365  |0 (DE-576)394592093  |4 aut 
700 1 |a Kool, Marcel  |e VerfasserIn  |0 (DE-588)1058669753  |0 (DE-627)797393560  |0 (DE-576)414823842  |4 aut 
700 1 |a Pfister, Stefan  |d 1974-  |e VerfasserIn  |0 (DE-588)123850215  |0 (DE-627)706450930  |0 (DE-576)293908400  |4 aut 
700 1 |a Kulozik, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1025736567  |0 (DE-627)723892032  |0 (DE-576)167091638  |4 aut 
700 1 |a Witt, Olaf  |d 1965-  |e VerfasserIn  |0 (DE-588)17275030X  |0 (DE-627)697681750  |0 (DE-576)133607410  |4 aut 
700 1 |a Deubzer, Hedwig  |d 1975-  |e VerfasserIn  |0 (DE-588)12991522X  |0 (DE-627)48365177X  |0 (DE-576)297900862  |4 aut 
773 0 8 |i Enthalten in  |t Journal of neuro-oncology  |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983  |g 110(2012), 3, Seite 335-348  |h Online-Ressource  |w (DE-627)32046122X  |w (DE-600)2007293-4  |w (DE-576)107058944  |x 1573-7373  |7 nnas  |a HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment 
773 1 8 |g volume:110  |g year:2012  |g number:3  |g pages:335-348  |g extent:14  |a HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment 
856 4 0 |u http://dx.doi.org/10.1007/s11060-012-0978-1  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1007/s11060-012-0978-1  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181129 
993 |a Article 
994 |a 2012 
998 |g 1058669753  |a Kool, Marcel  |m 1058669753:Kool, Marcel  |d 50000  |e 50000PK1058669753  |k 0/50000/  |p 5 
998 |g 134038398  |a Lodrini, Marco  |m 134038398:Lodrini, Marco  |d 50000  |e 50000PL134038398  |k 0/50000/  |p 2 
998 |g 12991522X  |a Deubzer, Hedwig  |m 12991522X:Deubzer, Hedwig  |d 50000  |e 50000PD12991522X  |k 0/50000/  |p 13  |y j 
998 |g 17275030X  |a Witt, Olaf  |m 17275030X:Witt, Olaf  |d 910000  |d 910500  |e 910000PW17275030X  |e 910500PW17275030X  |k 0/910000/  |k 1/910000/910500/  |p 12 
998 |g 1025736567  |a Kulozik, Andreas  |m 1025736567:Kulozik, Andreas  |d 910000  |d 910500  |e 910000PK1025736567  |e 910500PK1025736567  |k 0/910000/  |k 1/910000/910500/  |p 11 
998 |g 123850215  |a Pfister, Stefan  |m 123850215:Pfister, Stefan  |d 910000  |d 910500  |e 910000PP123850215  |e 910500PP123850215  |k 0/910000/  |k 1/910000/910500/  |p 10 
998 |g 1043235361  |a Korshunov, Andrey  |m 1043235361:Korshunov, Andrey  |d 910000  |e 910000PK1043235361  |k 0/910000/  |p 4 
998 |g 1038311837  |a Milde, Till  |m 1038311837:Milde, Till  |d 910000  |d 910500  |e 910000PM1038311837  |e 910500PM1038311837  |k 0/910000/  |k 1/910000/910500/  |p 1  |x j 
999 |a KXP-PPN1584629665  |e 3035981981 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"physDesc":[{"extent":"14 S."}],"relHost":[{"language":["eng"],"part":{"pages":"335-348","volume":"110","extent":"14","issue":"3","year":"2012","text":"110(2012), 3, Seite 335-348"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentJournal of neuro-oncology","id":{"eki":["32046122X"],"zdb":["2007293-4"],"issn":["1573-7373"]},"recId":"32046122X","note":["Gesehen am 11.06.2018","Fortsetzung der Druck-Ausgabe"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1983-","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","publisher":"Springer Science + Business Media B.V ; Kluwer","dateIssuedKey":"1983"}],"pubHistory":["1.1983 -"],"title":[{"title":"Journal of neuro-oncology","title_sort":"Journal of neuro-oncology"}]}],"name":{"displayForm":["Till Milde, Marco Lodrini, Larissa Savelyeva, Andrey Korshunov, Marcel Kool, Lena M. Brueckner, André S. L. M. Antunes, Ina Oehme, Arnulf Pekrun, Stefan M. Pfister, Andreas E. Kulozik, Olaf Witt, Hedwig E. Deubzer"]},"id":{"eki":["1584629665"],"doi":["10.1007/s11060-012-0978-1"]},"recId":"1584629665","note":["Gesehen am 29.11.2018"],"origin":[{"dateIssuedDisp":"December 2012","dateIssuedKey":"2012"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment","title_sort":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment"}],"person":[{"given":"Till","family":"Milde","display":"Milde, Till","role":"aut"},{"given":"Marco","family":"Lodrini","display":"Lodrini, Marco","role":"aut"},{"role":"aut","display":"Korshunov, Andrey","family":"Korshunov","given":"Andrey"},{"family":"Kool","given":"Marcel","display":"Kool, Marcel","role":"aut"},{"display":"Pfister, Stefan","given":"Stefan","family":"Pfister","role":"aut"},{"display":"Kulozik, Andreas","given":"Andreas","family":"Kulozik","role":"aut"},{"family":"Witt","given":"Olaf","display":"Witt, Olaf","role":"aut"},{"display":"Deubzer, Hedwig","family":"Deubzer","given":"Hedwig","role":"aut"}]} 
SRT |a MILDETILLLHDMB03ISAN2012